T. Pajak

发表

Tissue Micro-Array: A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study Groups

Martha Milanes-Yearsley, M. Hammond, T. Pajak, 2002, Modern Pathology.

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

T. Pajak, J. Cox, J. Stetz, 1995, International journal of radiation oncology, biology, physics.

Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

J. Jacobs, T. Pajak, J. Cooper, 2004, The New England journal of medicine.

A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.

A. Garden, K. Ang, M. Chambers, 2004, International journal of radiation oncology, biology, physics.

Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.

J. Ajani, J. Roth, R. Ginsberg, 1998, The New England journal of medicine.

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

R. Weber, T. Pajak, J. Cooper, 2003, The New England journal of medicine.

A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003

Jay S. Cooper, Sharon A. Spencer, Christopher U. Jones, 1999 .

Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome: a Report by the Radiation Therapy Oncology Group.

P. Rubin, T. Pajak, C. Perez, 1989, International journal of radiation oncology, biology, physics.

Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer.

T. Pajak, W. Sause, J. Cox, 1997, Lung cancer.

Phase II study of ICRF-159 in non-Hodgkin's lymphomas.

T. Pajak, E. P. Flannery, M. Corder, 1978, Cancer treatment reports.

Analysis of the probability and risk of cause-specific failure.

T. Pajak, J. Cox, R. Caplan, 1994, International journal of radiation oncology, biology, physics.

The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial.

Edward S. Kim, S. Lippman, F. Khuri, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

r etinoblastoma and Phosphate and t ensin Homolog t umor Suppressor s: i mpact on Ductal c arcinoma i n Situ Progression

G. Schwartz, T. Pajak, E. Knudsen, 2012 .

Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03).

M. Suntharalingam, T. Pajak, K. Fu, 2007, International journal of radiation oncology, biology, physics.

Definitive radiotherapy ± erythropoietin for squamous cell carcinma of the head and neck: Preliminary report of RTOG 99–03

M. Suntharalingam, T. Pajak, K. Fu, 2004 .

Hyperfractionated or accelerated radiotherapy for head and neck cancer.

K. Ang, J. Horiot, J. Pignon, 2010, The Cochrane database of systematic reviews.

Treatment of head and neck cancer.

T. Pajak, J. Ridge, A. Trotti, 2008, The New England journal of medicine.

Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.

D. Neuberg, R. Ginsberg, T. Pajak, 1999, International journal of radiation oncology, biology, physics.

Gender as a Determinant of Palliative Radiotherapy: A Patterns-of-Care-Study Analysis

T. Pajak, A. Hanlon, G. Hanks, 1994 .

Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor

T. Pajak, A. Godwin, B. Eisenberg, 2009, Molecular Cancer Therapeutics.

Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.

A. Garden, J. Coyne, T. Pajak, 2008, International journal of radiation oncology, biology, physics.

LENT: a good beginning but...

T. Pajak, C. Scott, 1995, International journal of radiation oncology, biology, physics.

Emotional well‐being does not predict survival in head and neck cancer patients

K. Ang, J. Coyne, T. Pajak, 2008, Cancer.

A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity

R. Weber, T. Pajak, R. Wheeler, 2010 .

TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.

A. Garden, K. Ang, W. Curran, 2007, The Lancet. Oncology.

Compliance with breast‐conservation standards for patients with early‐stage breast carcinoma

T. Pajak, M. Morrow, D. Winchester, 2003, Cancer.

Results of re-excisional biopsy of the primary tumor in preparation for definitive irradiation of patients with early stage breast cancer.

T. Pajak, B. Fowble, L. Solin, 1986, International journal of radiation oncology, biology, physics.

Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies.

C. Bloomfield, T. Pajak, N. Nissen, 1982, Cancer treatment reports.

Lung cancer as a second primary

T. Pajak, R. Hill, B. Greenberg, 1978, Cancer.

Locally recurrent breast carcinoma: the effect of adjuvant chemotherapy on prognosis.

T. Pajak, L. Coia, S. Kramer, 1983, Radiology.

Combination chemotherapy of non-Hodgkin lymphoma.

T. Pajak, N. Nissen, J. Holland, 1978, Medical and pediatric oncology.

Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study.

T. Pajak, L. H. Maurer, L. Maurer, 1981, Cancer treatment reports.

Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24.

T. Pajak, J. Cooper, J. Beitler, 1997, International journal of radiation oncology, biology, physics.

Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.

T. Pajak, J. Harley, Cooper, 1979, Blood.

Outcome comparisons of four radiation therapy oncology group (RTOG) trials in patients with stage IV-T4 head and neck (H/N) cancer: Encouraging results using intra-arterial (IA) cisplatin (P) and concurrent radiation therapy (RT).

A. Garden, K. Ang, T. Pajak, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting the response of head and neck cancers to radiation therapy with a multivariate modelling system: an analysis of the RTOG head and neck registry.

P. Rubin, T. Pajak, L. Brady, 1984, International journal of radiation oncology, biology, physics.

A comparative study of a bcnu containing 4‐drug program versus mopp versus 3‐drug combinations in advanced Hodgkin's disease. A cooperative study by the cancer and leukemia group B

T. Pajak, C. Spurr, J. Harley, 1979, Cancer.

Impact of initial quality control review on study outcome in lung and head/neck cancer studies--review of the Radiation Therapy Oncology Group experience.

T. Pajak, G. Laramore, C. Perez, 1989, International journal of radiation oncology, biology, physics.

Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.

Edward S. Kim, S. Lippman, F. Khuri, 2006, Journal of the National Cancer Institute.

Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity.

T. Pajak, R. Chlebowski, J. Bateman, 1980, Cancer treatment reports.

The superiority of CCNU in the treatment of advanced hodgkin's disease: Cancer and leukemia group b study

T. Pajak, H. Hansen, C. Spurr, 1981, Cancer.

Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study.

T. Pajak, N. Nissen, A. Gottlieb, 1982, Cancer treatment reports.

Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

J. Jacobs, T. Pajak, G. Laramore, 1988, Seminars in oncology.

In response to Dr. Denham et al.

T. Pajak, J. Cox, R. Caplan, 1996 .

Chemotherapy as predictor of compliance

J. Jacobs, T. Pajak, G. Laramore, 1994, Journal of surgical oncology.

Adriamycin versus adriamycin and bleomycin in advanced epidermoid carcinoma of the cervix.

T. Pajak, J. Bateman, C. Kardinal, 1977, Cancer treatment reports.

Hyperfractionated or accelerated radiotherapy for head and neck cancer.

K. Ang, J. Horiot, J. Pignon, 2010 .

Cyclophosphamide, doxorubicin, vincristine, and low‐dose continuous infusion bleomycin in non‐Hodgkin's lymphoma: Cancer and leukemia group B study #7804

C. Bloomfield, T. Pajak, J. Blom, 1982 .

Chapter 14 – NITROSOUREAS IN THE THERAPY OF HODGKIN'S DISEASE

C. Bloomfield, T. Pajak, N. Nissen, 1981 .

Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy: an analysis of RTOG 9501/intergroup phase III trial

J. Jacobs, T. Pajak, J. Cooper, 2002 .

Response rate and survival in myeloma patients receiving prednisone alone.

T. Pajak, R. Kyle, O. Mcintyre, 1985, Medical and pediatric oncology.

Development of surgical quality‐control mechanisms in large‐scale prospective trials: Head and neck intergroup report

J. Jacobs, T. Pajak, D. Schuller, 1991, Head & neck.

Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.

T. Pajak, H. Dosik, S. Kochwa, 1982, Cancer treatment reports.

Effect of age on therapeutic response and survival in advanced Hodgkin's disease.

C. Bloomfield, T. Pajak, N. Nissen, 1982, Cancer treatment reports.

The radiation therapy oncology group experience altered fractionation in lung cancer

T. Pajak, W. Sause, B. Emami, 1993 .

Significant adbantage of chemo-radiotherapy compared to radiation alone in randomized phase III trial for patients with esophageal cancer: An intergroup study

T. Pajak, J. Cooper, B. Emami, 1991 .

Head and neck cancer committee

R. Weber, F. Khuri, T. Pajak, 2001 .

Precisely defining high‐risk operable head and neck tumors based on rtog #85‐03 and #88‐24: Targets for postoperative radiochemotherapy?

K. Ang, J. Jacobs, T. Pajak, 1998, Head & neck.

Breast cancer in young women treated definitively with radiotherapy: An early report

T. Pajak, L. Solin, R. Goodman, 1984, American journal of clinical oncology.

Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group

P. Rubin, T. Pajak, C. Perez, 1987, Cancer.

Thymic irradiation. An approach to chronic lymphocytic leukemia.

T. Pajak, C. Spurr, F. Richards, 1974, American Journal of Medicine.

A Phase III Trial to Compare Standard Versus Accelerated Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Compliance and Toxicity

R. Weber, T. Pajak, D. Rosenthal, 2007 .

Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study.

T. Pajak, R. Silver, B. Kennedy, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for loco/regional control and metastasis and the impact on survival.

T. Pajak, C. Maclean, S. Kramer, 1986, International journal of radiation oncology, biology, physics.

Analysis of neutron radiotherapy treatment complications.

T. Pajak, G. Laramore, T. Griffin, 1986, Bulletin du cancer.

The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol.

K. Shin, T. Pajak, B. Emami, 1993, International journal of radiation oncology, biology, physics.

Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer.

T. Pajak, E. Vokes, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined therapy for resectable head and neck cancer. A phase 3 intergroup study.

J. Jacobs, T. Pajak, G. Laramore, 1989, Archives of otolaryngology--head & neck surgery.

Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies.

T. Pajak, W. Sause, C. Perez, 1994, Lung cancer.

Chapter 26 – NITROSOUREAS IN THE TREATMENT OF MULTIPLE MYELOMA

T. Pajak, J. Harley, R. Kyle, 1981 .

Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.

K. Ang, J. Jacobs, T. Pajak, 2012, International journal of radiation oncology, biology, physics.

The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited

V. Grégoire, T. Pajak, J. Cooper, 2017, Cancer.

1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531

D. Grignon, T. Pajak, G. Hanks, 1997 .

Does residual tumor adversely impact on the outcome of patients undergoing definitive irradiation for early stage breast cancer

T. Pajak, B. Fowble, L. Solin, 1986 .

Survey of brachytherapy practice in the United States: a report of the Clinical Research Committee of the American Endocurietherapy Society.

J. Blasko, S. Nag, T. Pajak, 1995, International journal of radiation oncology, biology, physics.

Interfraction interval is major determinant of late effects, but not acute effects or tumor control, with hyperfractionated irradiation (HFX) of carcinomas of upper respiratory and digestive tracts (URDT)

P. Rubin, T. Pajak, K. Fu, 1990 .

Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B

C. Bloomfield, T. Pajak, N. Nissen, 1980, Cancer.

Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience.

P. Rubin, T. Pajak, J. Cooper, 1989, International journal of radiation oncology, biology, physics.

Vincristine, prednisone and L‐asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse

T. Pajak, W. Nyhan, F. Kung, 1978, Cancer.

Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study.

T. Pajak, G. Laramore, M. Maor, 1988, International journal of radiation oncology, biology, physics.

A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

A. Garden, T. Pajak, J. Cooper, 2000, International journal of radiation oncology, biology, physics.

Fast Neutron Radiation for Inoperable and Recurrent Salivary Gland Cancers

K. Russell, T. Pajak, G. Laramore, 1989, American journal of clinical oncology.

Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.

L. Norton, L. Norton, T. Pajak, 1982, Annals of internal medicine.

Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.

F. Cavalli, T. Pajak, K. Rai, 1980, Blood.

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

N. Petrelli, S. Doggett, T. Pajak, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

R. Weber, T. Pajak, J. Cooper, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

Brian O'Sullivan, Jacques Bernier, Richard Sylvester, 2006, The Lancet.

Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal

T. Pajak, L. Coia, K. Paris, 1999, Cancer.

Randomized clinical trial of cystosine arabinoside and 6‐thioguanine in remission induction and consolidation of adult nonlymphocytic acute leukemia

T. Pajak, J. Bateman, Jerry P. Lewis, 1977, Cancer.

Radiation therapy alone or in combination with surgery in head and neck cancer

T. Pajak, V. Marcial, Victor A. Marcial, 1985, Cancer.

A randomized combined modality trial in small cell carcinoma of the lung comparison of combination chemotherapy‐radiation therapy versus cyclophosphamide‐radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation

T. Pajak, J. Blom, R. Weiss, 1980, Cancer.

A new effective four‐drug combination of CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosourea) (NSC‐79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease

T. Pajak, C. Spurr, N. Nissen, 1980, Cancer.

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience

T. Pajak, R. Kyle, E. Henderson, 1982, Cancer.

The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study.

T. Pajak, G. Hanks, R. Lanciano, 1993, International journal of radiation oncology, biology, physics.

Multimodality therapy of localized unresectable pancreatic adenocarcinoma

T. Pajak, L. Solin, M. Mohiuddin, 1984, Cancer.

INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

R. Ginsberg, R. Komaki, T. Pajak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylactic Extended-Field Irradiation of Para-aortic Lymph Nodes in Stages IIB and Bulky IB and IIA Cervical Carcinomas: Ten-Year Treatment Results of RTOG 79-20

P. Grigsby, T. Pajak, J. Cooper, 1995 .

Excisional biopsy, axillary node dissection and definitive radiotherapy for Stages I and II breast cancer.

T. Pajak, L. Solin, R. Goodman, 1985, International journal of radiation oncology, biology, physics.

Induction chemotherapy in advanced head and neck cancer. A Radiation Therapy Oncology Group Study.

J. Jacobs, T. Pajak, S. Leibel, 1987, Archives of otolaryngology--head & neck surgery.

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

D. Grignon, T. Pajak, H. Sandler, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fast neutrons and misonidazole for malignant astrocytomas.

T. Pajak, R. T. Ten Haken, J. Nelson, 1985, International journal of radiation oncology, biology, physics.

Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)

M. van Glabbeke, J. Jacobs, J. Bourhis, 2005, Head & neck.

Failure of cricopharyngeal myotomy to improve dysphagia following head and neck cancer surgery.

J. Jacobs, T. Pajak, J. Logemann, 1999, Archives of otolaryngology--head & neck surgery.

Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study

T. Pajak, J. Cooper, J. Ensley, 1987, Cancer.

Carcinomas of the oropharynx treated with hyperfractionated radiation therapy on Radiation Therapy Oncology Group Protocol 8313.

S. McDonald, T. Pajak, K. Fu, 1994, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Surgical quality control in head and neck cancer. Study 73-03 of the Radiation Therapy Oncology Group.

L. Lowry, T. Pajak, J. Snow, 1989, Archives of otolaryngology--head & neck surgery.

Microvessel Density ≥60 Does Not Predict for Outcome After Radiation Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: Results of a Correlative Study From the Radiation Therapy Oncology Group (RTOG) 90-03 Trial

Christopher U. Jones, K. Ang, M. Hammond, 2007, American journal of clinical oncology.

Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials.

A. Garden, J. Coyne, T. Pajak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and prognosis of patients with astrocytoma with atypical or anaplastic features

D. Nelson, T. Pajak, J. Nelson, 2005, Journal of Neuro-Oncology.

In response to Drs. Dubben, Beck-Bornholdt, and Llogie.

K. Ang, T. Pajak, K. Fu, 2002, International journal of radiation oncology, biology, physics.

% SE At risk % SE At risk % SE At risk % SE At risk

T. Pajak, K. Fu, B. Berkey, 2002 .

Combined-Modal i ty Therapy for Esophageal Cancer : High-Dose Versus Standard-Dose Radiat ion Therapy

R. Ginsberg, R. Komaki, T. Pajak, 2002 .

p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610.

D. Grignon, R. Abrams, F. Sarkar, 1997, Journal of the National Cancer Institute.

Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08.

S. McDonald, T. Pajak, J. Cooper, 1994, International journal of radiation oncology, biology, physics.

Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.

T. Pajak, B. Emami, J. Cox, 1993, International journal of radiation oncology, biology, physics.

5-year results of cisplatin and fluorouracil infusion in head and neck cancer.

J. Jacobs, L. Lowry, T. Pajak, 1991, Archives of otolaryngology--head & neck surgery.

Elapsed treatment days--a critical item for radiotherapy quality control review in head and neck trials: RTOG report.

W. Curran, P. Rubin, T. Pajak, 1991, International journal of radiation oncology, biology, physics.

Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long‐term results of the radiation therapy oncology group study 81‐17

W. Curran, T. Pajak, J. Cooper, 1990, Cancer.

Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study.

T. Pajak, J. Cooper, M. Mohiuddin, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mixed neutron/photon irradiation of unresectable squamous cell carcinomas of the head and neck: the final report of a randomized cooperative trial.

T. Pajak, G. Laramore, M. Maor, 1989, International journal of radiation oncology, biology, physics.

A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).

T. Pajak, J. Stetz, S. Order, 1989, International journal of radiation oncology, biology, physics.

Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.

T. Pajak, E. Henderson, S. Rafla, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.

T. Pajak, T. Wasserman, J. Stetz, 1987, International journal of radiation oncology, biology, physics.

A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial.

R. Komaki, T. Pajak, T. Phillips, 1987, International journal of radiation oncology, biology, physics.

Improved response and survival to combined cisplatin and radiation in non‐keratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors

T. Pajak, R. Zarbo, J. Crissman, 1987, Cancer.

Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG).

T. Pajak, J. Stetz, L. Tupchong, 1987, International journal of radiation oncology, biology, physics.

Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study.

T. Pajak, E. Henderson, W. Eaton, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease.

C. Bloomfield, T. Pajak, N. Nissen, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.

T. Pajak, R. Kyle, E. Henderson, 1982, Cancer treatment reports.

The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)-analysis of a radiation therapy oncology group (RTOG) protocol

K. Shin, T. Pajak, B. Emami, 1993 .

Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy.

T. Pajak, J. Cooper, J. Ensley, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.

Daniel S. Miller, D. Bostwick, D. Grignon, 2000, Archives of pathology & laboratory medicine.

College of American Pathologists Conference XXXV: solid tumor prognostic factors-which, how and so what? Summary document and recommendations for implementation. Cancer Committee and Conference Participants.

C. Compton, D. Bostwick, D. Grignon, 2000, Archives of pathology & laboratory medicine.

Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03.

K. Ang, J. Erler, T. Pajak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technically accurate intracavitary insertions improve pelvic control and survival among patients with locally advanced carcinoma of the uterine cervix.

T. Pajak, A. Hanlon, B. Corn, 1994, Gynecologic oncology.

Effect of the methanol extraction residue of Bacillus Calmette‐Guerin in advanced Hodgkin's disease

T. Pajak, N. Nissen, A. Gottlieb, 1982 .

Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.

C. Coleman, T. Pajak, J. Stetz, 1997, International journal of radiation oncology, biology, physics.

26: A Randomized Trial of Hyperfractionation Versus Standard Fractionation In T2 Squamous Cell Carcinoma of The Vocal Cord

Christopher U. Jones, K. Ang, T. Pajak, 2006 .

Statistical issues in tumor marker studies.

D. Sargent, M. Hammond, T. Pajak, 2000, Archives of pathology & laboratory medicine.

Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience

T. Pajak, S. Kochwa, M. Or, 1979 .

Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

F. Cavalli, T. Pajak, N. Nissen, 1981 .

Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B.

T. Pajak, K. Propert, N. Nissen, 1986, Journal of Clinical Oncology.

The management of malignant gliomas with radiation therapy: Therapeutic results and research strategies

T. Pajak, S. Leibel, C. Scott, 1991 .

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

F. Cavalli, T. Pajak, N. Nissen, 1981, Cancer.

light chains: CALGB experience Response to therapy in IgG myeloma patients excreting lambda or kappa

T. Pajak, B. Weksler, S. Kochwa, 2011 .

Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience.

T. Pajak, B. Weksler, S. Kochwa, 1979, Blood.

Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.

A. Markoe, T. Pajak, K. Paris, 1996, The cancer journal from Scientific American.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

Tomasz Burzykowski, Marc Buyse, Stefan Michiels, 2009, The Lancet. Oncology.

Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433.

W. Curran, R. Komaki, T. Pajak, 1993, Lung cancer.

Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up.

S. Lippman, W. Hong, T. Pajak, 1994, Journal of the National Cancer Institute.

Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer.

J. Jacobs, T. Pajak, J. Cooper, 1996, International journal of radiation oncology, biology, physics.

136 Dose escalation without split-course chemoradiation for anal cancer: Results of a phase II RTOG study

T. Pajak, W. Pinover, R. Myerson, 1997 .

The radiation therapy oncology group: An update of clinical research activities

T. Pajak, T. Phillips, S. Leibel, 1991 .

Twice‐daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the radiation therapy oncology group 88—05

P. Grigsby, T. Pajak, S. Leibel, 1994, Cancer.

interruptions adversely affect local control and survival with hyperfractionated radiation therapy of carcinomas of the upper respiratory and digestive tracts new evidence for accelerated proliferation from radiation therapy oncology group protocol 8313

P. Rubin, T. Pajak, K. Fu, 1992, Cancer.

Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.

P. Rubin, T. Pajak, K. Fu, 1990, International journal of radiation oncology, biology, physics.

RTOG ALTERED FRACTIONATION TRIALS

D. Nelson, T. Pajak, K. Fu, 1992 .

A Radiation Therapy Oncology Group experience: chemotherapy/radiation therapy of lung cancer

T. Pajak, W. Sause, C. Perez, 1993 .

ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313.

P. Rubin, T. Pajak, K. Fu, 1991, International journal of radiation oncology, biology, physics.

Long Term Outcomes of RTOG 90–03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma

Sharon A. Spencer, Christopher U. Jones, J. S. Cooper, 2005 .

Considerations in designing and analyzing surgical adjuvant study in resected stage I and II carcinoma of the lung

T. Pajak, J. Bateman, B. Greenberg, 1979, Cancer.

C. Compton, D. Bostwick, D. Grignon, 2000, Archives of pathology & laboratory medicine.

Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.

R. Abrams, T. Pajak, S. Asbell, 1998, The cancer journal from Scientific American.

Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer.

M. J. Gallagher, S. Lippman, T. Pajak, 1994, Journal of the National Cancer Institute.

The effect of adjuvant chemotherapy on cosmesis and complications in patients with breast cancer treated by definitive irradiation.

T. Pajak, J. Glick, D. Haller, 1983, International journal of radiation oncology, biology, physics.

A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.

T. Pajak, B. Emami, R. Doggett, 1993, International journal of radiation oncology, biology, physics.

Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history.

R. Abrams, T. Pajak, B. Epstein, 1999, American journal of clinical oncology.

Preliminary report on phase III RTOG studies of extended-field irradiation in carcinoma of the prostate.

L. Kalish, T. Pajak, S. Asbell, 1982 .

Chemotherapy following Surgery for Head and Neck Cancer: A Radiation Therapy Oncology Group Study

J. Jacobs, T. Pajak, S. Leibel, 1989, American journal of clinical oncology.

Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13.

P. Rubin, T. Pajak, K. Fu, 1995, International journal of radiation oncology, biology, physics.

PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation.

G E Hanks, T. Pajak, C. Perez, 1994, International journal of radiation oncology, biology, physics.

Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression.

G. Schwartz, T. Pajak, E. Knudsen, 2012, Journal of the National Cancer Institute.

Randomized dose-searching phase ILE/II trials of fractionation in radiation therapy for cancer.

T. Pajak, J. Cox, M. Diener-West, 1991, Journal of the National Cancer Institute.

Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience.

T. Pajak, G. Cornwell, O. R. Mcintyre, 1979, Cancer treatment reports.

In response to bentzen and thames: Regarding dose-response relationships for late radiation effects in the head and neck: Analysis of RTOG 8313 trial, fu et al. IJROBP 32:577–588; 1995

T. Pajak, K. Fu, J. Cox, 1996 .

Evaluation of Preoperative Radiation Therapy in Operable Colorectal Cancer

T. Pajak, W. Sause, M. Mohiuddin, 1994, Annals of surgery.

Early Rehabilitative Care in Community Hospitals: Effect on Quality of Survivorship Following a Stroke

J. Toole, T. Pajak, B. Truscott, 1974, Stroke.

Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B.

T. Pajak, N. Nissen, J. Holland, 1977, Cancer treatment reports.

Statistical power for a long-term survival trial with a time-dependent treatment effect.

T. Pajak, J. Lu, 2000, Controlled clinical trials.

Statistical response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.

T. Pajak, D. Cosmatos, 1995, International journal of radiation oncology, biology, physics.

Reply to Emotional Well‐Being Does Not Predict Survival in Head and Neck Cancer Patients

J. Coyne, T. Pajak, D. Watkins Bruner, 2008 .

Bleomycin (NSC-125066) therapy of responsive solid tumors.

T. Pajak, J. Bateman, R. Pugh, 1976, Oncology.

Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03.

J. Jacobs, L. Lowry, T. Pajak, 1991, International journal of radiation oncology, biology, physics.

Interruptions of high-dose radiation therapy for non-small cell carcinoma of the lung decrease long-term survival in favorable patients

T. Pajak, B. Emami, J. Cox, 1992 .

College of American Pathologists Conference XXXV: Solid Tumor Prognostic Factors—Which, How and So What?

C. Compton, D. Bostwick, D. Grignon, 2009 .

Chapter 16 – CCNU IN COMBINATION CHEMOTHERAPY FOR SMALL-CELL LUNG CANCER

T. Pajak, R. Comis, S. Ginsberg, 1981 .

Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20.

T. Pajak, M. Rotman, V. Marcial, 1995, JAMA.

Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study.

T. Pajak, C. Spurr, J. Harley, 1979, Medical and pediatric oncology.

In response to Bentzen et al., IJROBP 32:1531-1534; 1995.

T. Pajak, J. Cox, R. Caplan, 1995, International journal of radiation oncology, biology, physics.

Phase II study of chlorozotocin in non-small cell carcinoma of the lung.

T. Pajak, D. Hoth, C. J. Cornell, 1981, Cancer treatment reports.

Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.

T. Pajak, J. Bateman, F. Bull, 1975, Oncology.

Small cell anaplastic carcinoma of the lung. The Cancer and Leukemia Group B Experience.

T. Pajak, R. Comis, A. Chahinian, 1982, Bulletin du Cancer.

Workshop report: Organ preservation strategies in advanced head and neck cancer—Current status and future directions

K. Ang, D. Kraus, T. Pajak, 1999, Head & neck.

Fast neutron therapy for malignant astrocytomas

T. Pajak, J. Nelson, T. Griffin, 2004, Journal of Neuro-Oncology.

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis

K. Ang, J. Horiot, J. Pignon, 2006, The Lancet.

Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.

M. Buyse, J. Pignon, T. Pajak, 2009, The Lancet. Oncology.

Treatment of advanced lymphomas with bleomycin (NSC-125066).

T. Pajak, P. Rosen, J. Bateman, 1976, Oncology.

Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

F. Cavalli, T. Pajak, N. Nissen, 1981, Cancer.

Applications of Data Bases and AI/Expert Systems in Radiation Therapy

M. D. Altschuler, T. Pajak, S. Zink, 1988, American journal of clinical oncology.

Evaluation of a Neutron Boost in Head and Neck Cancer Results of the Randomized RTOG Trial 78–08

T. Pajak, D. Schoenfeld, M. Maor, 1986, American journal of clinical oncology.